Lantern Pharma News

Follow[dot]Health is a news alert service for Heathcare and Healthtech. We are following 40K entities across 30M news items - with 1M items added monthly. This is selected news for Lantern Pharma, which is filed under Sectors / Healthtech. There are 391 news items for this page.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source
6/21/2022 Sanders Morris Harris LLC Purchases 47,803 Shares of Lantern Pharma Inc. (NASDAQ:LTRN)
Sanders Morris Harris LLC grew its position in shares of Lantern Pharma Inc. ( NASDAQ:LTRN – Get Rating ) by 14.2% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 384,228 shares of the company’s stock after purchasing an ...
dispatchtribunal.com
6/21/2022 Sanders Morris Harris LLC Boosts Stock Position in Lantern Pharma Inc. (NASDAQ:LTRN)
Sanders Morris Harris LLC boosted its holdings in Lantern Pharma Inc. ( NASDAQ:LTRN – Get Rating ) by 14.2% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 384,228 shares of the company’s stock after purchasing an ...
theenterpriseleader.com
6/21/2022 Sanders Morris Harris LLC Boosts Stock Position in Lantern Pharma Inc. (NASDAQ:LTRN)
Sanders Morris Harris LLC boosted its holdings in Lantern Pharma Inc. ( NASDAQ:LTRN – Get Rating ) by 14.2% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 384,228 shares of the company’s stock after purchasing an ...
thelincolnianonline.com
6/16/2022 Lantern Pharma Inc. (NASDAQ:LTRN) Sees Large Decrease in Short Interest thecerbatgem.com
6/14/2022 Lantern Pharma Inc. (NASDAQ:LTRN) Sees Significant Decline in Short Interest - Transcript Daily transcriptdaily.com
6/14/2022 Lantern Pharma Inc. (NASDAQ:LTRN) Sees Significant Decline in Short Interest - Stock Observer thestockobserver.com
6/13/2022 Lantern Pharma Inc. (NASDAQ:LTRN) Short Interest Update Daily Political
6/13/2022 Lantern Pharma Inc. (NASDAQ:LTRN) Short Interest Update etfdailynews.com
6/2/2022 Advisor Group Holdings Inc. Buys 2,561 Shares of Lantern Pharma Inc. (NASDAQ:LTRN) American Banking News
6/2/2022 Advisor Group Holdings Inc. Buys 2,561 Shares of Lantern Pharma Inc. (NASDAQ:LTRN) - Ticker Report Ticker Report
5/30/2022 Envestnet Asset Management Inc. Takes $84,000 Position in Lantern Pharma Inc. (NASDAQ:LTRN) American Banking News
5/30/2022 Envestnet Asset Management Inc. Buys New Stake in Lantern Pharma Inc. (NASDAQ:LTRN) baseballnewssource.com
5/28/2022 Lantern Pharma (NASDAQ:LTRN) Trading Down 0.3% Mayfield Recorder
5/28/2022 Lantern Pharma (NASDAQ:LTRN) Trading Down 0.3% Dakota Financial News
5/12/2022 Lantern Pharma to Host Virtual KOL Event on Glioblastoma Multiforme (GBM) with Collaborators from Johns Hopkins during Brain Tumor Awareness Month PR Newswire
5/5/2022 Lantern Pharma Management to Speak at Multiple Investor and Scientific Conferences in May 2022 Business Wire
5/3/2022 Lantern Pharma Reports First Quarter 2022 Financial Results and Operational Highlights PR Newswire
4/26/2022 Lantern Pharma's Board of Directors Names Maria Maccecchini, Ph.D. as a Director Nominee to Lantern's Board of Directors PR Newswire
4/22/2022 Lantern Pharma to Report First Quarter 2022 Operating & Financial Results on May 3rd, 2022 at 4:30 p.m. ET PR Newswire
3/22/2022 Lantern Pharma board extends existing share repurchase program Seeking Alpha
3/22/2022 Lantern Pharma Announces Extension of Existing Share Repurchase Program PR Newswire
3/14/2022 Lantern Pharma to Present Positive Preclinical Data on the Effectiveness of LP-184 in Brain Metastases at the American Association of Cancer Research (AACR) Annual Meeting PR Newswire
3/10/2022 Lantern Pharma Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Operational Highlights PR Newswire
2/15/2022 Lantern Pharma Expands into Additional Pediatric Cancers Through a Collaboration with The Greehey Children's Cancer Research Institute (GCCRI) at University of Texas Health Science Center-San Antonio PR Newswire
1/24/2022 Lantern Pharma Receives Rare Pediatric Disease and Orpan Drug Designations for LP-184 for the Treatment of Atypical Teratoid Rhabdoid Tumor (ATRT) - an Aggressive and Rapidly Growing Form of Cancer of the Central Nervous System PR Newswire